Table 3.
Multivariate cox regression analysis of prognostic factors for LA-NPC patients.
| Variables | HR (95% CI) | P |
|---|---|---|
| OS | ||
| EBV DNA status (positive vs negative) | 6.456 (1.496–7.871) | 0.012 |
| Nodal classification (N2-3 vs N0-1) | 2.167 (0.500–9.391) | 0.301 |
| Clinical stage (IVA vs III) | 9.355 (2.588–14.731) | 0.004 |
| Pretreatment SII level (≥432.48 vs <432.48) | 3.977 (0.709–7.314) | 0.073 |
| IC regimen (TP vs TPF) | 1.880 (0.778–4.545) | 0.161 |
| PFS | ||
| EBV DNA status (positive vs negative) | 5.254 (2.242–12.314) | 0.001 |
| Nodal classification (N2-3 vs N0-1) | 0.887 (0.637–1.236) | 0.480 |
| Clinical stage (IVA vs III) | 4.956 (5.898–12.845) | 0.001 |
| Pretreatment SII level (≥432.48 vs <432.48) | 2.801 (1.195–6.565) | 0.018 |
| IC regimen (TP vs TPF) | 1.604 (0.941–2.736) | 0.083 |
| LRFS | ||
| EBV DNA status (positive vs negative) | 3.358 (1.162–9.700) | 0.025 |
| Nodal classification (N2-3 vs N0-1) | 0.665 (0.303–1.463) | 0.311 |
| Clinical stage (IVA vs III) | 1.479 (2.477–7.839) | 0.004 |
| Pretreatment SII level (≥432.48 vs <432.48) | 0.665 (0.303–1.463) | 0.086 |
| IC regimen (TP vs TPF) | 1.036 (0.495–2.172) | 0.924 |
| DMFS | ||
| EBV DNA status (positive vs negative) | 9.871 (2.332–4.774) | 0.002 |
| Nodal classification (N2-3 vs N0-1) | 4.076 (0.962–7.267) | 0.046 |
| Clinical stage (IVA vs III) | 5.201 (2.769–5.011) | 0.010 |
| Pretreatment SII level (≥432.48 vs <432.48) | 3.735 (1.121–12.441) | 0.032 |
| IC regimen (TP vs TPF) | 2.182 (1.002–4.751) | 0.049 |
EBV DNA, Epstein-Barr virus DNA; SII, systemic immune-inflammation index; IC, induction chemotherapy; TPF, docetaxel, cisplatin, and 5-fluorouracil; TP, docetaxel and cisplatin; OS, overall survival; PFS, progression-free survival; LRFS, locoregional relapse-free survival; DMFS, distant metastasis-free survival; HR, hazard ratio; CI, confidence interval.